SEC Comment Letter 0000000000-23-005591 to BELITE BIO, INC (BLTE) (CIK 0001889109) (BLTE)
BELITE BIO, INC (BLTE) (CIK 0001889109)
Date: May 25, 2023 · CIK: 0001889109 · Accession: 0000000000-23-005591
AI Filing Summary & Sentiment
File numbers found in text: 333-272125
Letter
United States securities and exchange commission logo May 25, 2023 Yu-Hsin Lin Chief Executive Officer Belite Bio, Inc 12750 High Bluff Drive Suite 475 San Diego, CA 92130 Re:Belite Bio, Inc Registration Statement on Form F-3 Filed May 22, 2023 File No. 333-272125 Dear Yu-Hsin Lin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Portia Ku, Esq.
Show Raw Text
United States securities and exchange commission logo
May 25, 2023
Yu-Hsin Lin
Chief Executive Officer
Belite Bio, Inc
12750 High Bluff Drive Suite 475
San Diego, CA 92130
Re:Belite Bio, Inc
Registration Statement on Form F-3
Filed May 22, 2023
File No. 333-272125
Dear Yu-Hsin Lin:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Portia Ku, Esq.